A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients

NCT01523990 | Completed Phase 1

• 1 other identifier: TG-2349-01
• Study Type: interventional
• Target: 135
• Locations: 1 country
• Sites: 1

Brief Summary

A Safety Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in HCV Genotype 1 Infected Patients

Conditions

Healthy; Hepatitis C, Chronic

Outcome Measures

Primary Outcomes (5)

• Pharmacokinetics (PK) profiles of single and multiple ascending oral doses of TG-2349 in healthy East Asian and Caucasian volunteers.

  Dose proportionality will be assessed by evaluating PK parameters AUC0-t, AUC0-inf, and Cmax. Parameters that are not dose dependent will be assessed by evaluating Tmax, t1/2, and λz. The linear relationship between the log-transformed PK parameter and the natural log of the dose will be tested using a linear lack-of-fit test. The dose-dependent parameters will not be dose normalized. Residual analysis will be used to assess the assumptions of normality and variance homogeneity for the statistical model.

  predose, and 1,2,3,4,6,8,12,24,36,48,72,96 hours post-dose

• Safety and tolerability of single and multiple ascending oral doses of TG-2349 in healthy East Asian and Caucasian volunteers.

  Vital signs, physical examinations, 12-lead ECG, safety laboratory parameter abnormalities, and other toxicities graded by the National Cancer Institute (NCI) Common Toxicity Criteria (CTC) version 4.0 will be examined to evaluate safety profiles of the study treatments. Special attention will be paid to Grade III or IV toxicities in all treatment levels.

  predose, and 2,4,6,8,12,24,48,72,96 hours post-dose

• Pharmacokinetics (PK) profiles of multiple oral doses of TG-2349 in genotype 1, 2, 3, 4, 5, and 6 HCV-infected patients.

  Dose proportionality will be assessed by evaluating PK parameters AUC0-t, AUC0-inf, and Cmax. Parameters that are not dose dependent will be assessed by evaluating Tmax, t1/2, and λz. The linear relationship between the log-transformed PK parameter and the natural log of the dose will be tested using a linear lack-of-fit test. The dose-dependent parameters will not be dose normalized. Residual analysis will be used to assess the assumptions of normality and variance homogeneity for the statistical model.

  predose, and 1,2,3,4,6,8,12,24,36,48,72,96 hours post-dose

• Safety and tolerability of multiple ascending oral doses of TG-2349 in genotype 1, 2, 3, 4, 5, and 6 HCV-infected patients.

  Vital signs, physical examinations, 12-lead ECG, safety laboratory parameter abnormalities, and other toxicities graded by the National Cancer Institute (NCI) Common Toxicity Criteria (CTC) version 4.0 will be examined to evaluate safety profiles of the study treatments. Special attention will be paid to Grade III or IV toxicities in all treatment levels.

  predose, and 4,6,12 hours post-dose

• Antiviral activity of multiple ascending oral doses of TG-2349 in genotype 1, 2, 3, 4, 5, and 6 HCV-infected patients.

  Descriptive statistics and graphs will be presented for the antiviral variables. Change from pre dose will be analyzed descriptively for each time point after study drug administration. Graphic displays of raw data and changes over time will be performed at each dosing level (plots of raw data of TG-2349 at each time point with mean and median). The breakthrough is defined as a greater than or equal to 1 log10 increase in HCV RNA above nadir, or detectable HCV RNA, while on treatment, after an initial drop to a level of below the detection. The slope of the plasma viral RNA decrease during the first few days of treatment, any subsequent plasma viral RNA increase observed during and/or after dosing, and all breakthrough events should be recorded and summarized.

  predose, and 1,2,3,4,6,8,12,24,36,48,72,96 hours post-dose

Secondary Outcomes (4)

• The food effect of TG-2349 in healthy volunteers.

  1 week

• Appearance of viral variants if any in genotype 1, 2, 3, 4, 5, and 6 HCV-infected patients.

  during and after 3 days of TG-2349 dosing, the 4-week and 1 year follow-up periods

• Ethnicity differences in safety and tolerability between East Asian and Caucasian volunteers.

  predose, and 2,4,6,8,12,24,48,72,96 hours post-dose

• Ethnicity differences in Pharmacokinetics (PK) profiles between East Asian and Caucasian volunteers.

  predose, and 1,2,3,4,6,8,12,24,36,48,72,96 hours post-dose

Study Arms (27)

Panel I (TG-2349)

EXPERIMENTAL

Sequential single oral dose taken by healthy East and Caucasian volunteers from 50 mg (fasted) to 50 mg (fed) of TG-2349 with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.

Drug: TG-2349

Panel I (placebo)

PLACEBO COMPARATOR

Sequential single oral dose taken by healthy East and Caucasian volunteers from 50 mg (fasted) to 50 mg (fed) of placebo with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.

Drug: placebo

Panel II (TG-2349)

EXPERIMENTAL

Sequential single oral dose taken by healthy East and Caucasian volunteers from 100 mg (fasted) to 100 mg (fed) of TG-2349 with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.

Drug: TG-2349

Panel II (placebo)

PLACEBO COMPARATOR

Sequential single oral dose taken by healthy East and Caucasian volunteers from 100 mg (fasted) to 100 mg (fed) of placebo with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.

Drug: placebo

Panel III (TG-2349)

EXPERIMENTAL

Sequential single oral dose taken by healthy East and Caucasian volunteers from 200 mg (fasted or fed) to 400 mg (fasted or fed) of TG-2349 with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.

Drug: TG-2349

Panel III (placebo)

PLACEBO COMPARATOR

Sequential single oral dose taken by healthy East and Caucasian volunteers from 200 mg (fasted or fed) to 400 mg (fasted or fed) of placebo with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.

Drug: placebo

Panel IV (TG-2349)

EXPERIMENTAL

Sequential single oral dose taken by healthy East and Caucasian volunteers from 600 mg (fasted or fed) to 800 mg (fasted or fed) of TG-2349 with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.

Drug: TG-2349

Panel IV (placebo)

PLACEBO COMPARATOR

Sequential single oral dose taken by healthy East and Caucasian volunteers from 600 mg (fasted or fed) to 800 mg (fasted or fed) of placebo with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.

Drug: placebo

Panel V (TG-2349)

EXPERIMENTAL

Oral dose taken once daily for 5 consecutive days at dose level of 100 mg taken by healthy East and Caucasian volunteers .

Drug: TG-2349

Panel V (placebo)

PLACEBO COMPARATOR

Oral dose taken once daily for 5 consecutive days at dose level of 100 mg taken by healthy East and Caucasian volunteers .

Drug: placebo

Panel VI (TG-2349)

EXPERIMENTAL

Oral dose taken once daily for 5 consecutive days at dose level of 200 mg taken by healthy East and Caucasian volunteers .

Drug: TG-2349

Panel VI (placebo)

PLACEBO COMPARATOR

Oral dose taken once daily for 5 consecutive days at dose level of 200 mg taken by healthy East and Caucasian volunteers .

Drug: placebo

Panel VII (TG-2349)

EXPERIMENTAL

Oral dose taken once daily for 5 consecutive days at dose level of 400 mg taken by healthy East and Caucasian volunteers .

Drug: TG-2349

Panel VII (placebo)

PLACEBO COMPARATOR

Oral dose taken once daily for 5 consecutive days at dose level of 400 mg taken by healthy East and Caucasian volunteers .

Drug: placebo

Panel VIII (TG-2349)

EXPERIMENTAL

Oral dose taken once daily for 5 consecutive days at dose level of 600 mg taken by healthy East and Caucasian volunteers .

Drug: TG-2349

Panel VIII (placebo)

PLACEBO COMPARATOR

Oral dose taken once daily for 5 consecutive days at dose level of 600 mg taken by healthy East and Caucasian volunteers .

Drug: placebo

Panel IX (TG-2349)

EXPERIMENTAL

Oral dose taken once daily for 3 consecutive days at dose level of 200 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.

Drug: TG-2349

Panel IX (placebo)

PLACEBO COMPARATOR

Oral dose taken once daily for 3 consecutive days at dose level of 200 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.

Drug: placebo

Panel X (TG-2349)

EXPERIMENTAL

Oral dose taken once daily for 3 consecutive days at dose level of 400 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.

Drug: TG-2349

Panel X (placebo)

PLACEBO COMPARATOR

Oral dose taken once daily for 3 consecutive days at dose level of 400 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.

Drug: placebo

Panel XI (TG-2349)

EXPERIMENTAL

Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.

Drug: TG-2349

Panel XI (placebo)

PLACEBO COMPARATOR

Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.

Drug: placebo

Panel XII (TG-2349)

EXPERIMENTAL

Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 2 infected, treatment-naive patients.

Drug: TG-2349

Panel XIII (TG-2349)

EXPERIMENTAL

Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 3 infected, treatment-naive patients.

Drug: TG-2349

Panel XIV (TG-2349)

EXPERIMENTAL

Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 4 infected, treatment-naive patients.

Drug: TG-2349

Panel XV (TG-2349)

EXPERIMENTAL

Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 5 infected, treatment-naive patients.

Drug: TG-2349

Panel XVI (TG-2349)

EXPERIMENTAL

Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 6 infected, treatment-naive patients.

Drug: TG-2349

Interventions

TG-2349 DRUG

Supplied as oral liquid formulation in pre-filled glass syringe. Two dose strengths, 25 mg TG-2349 (25 mg/mL in PEG 400, 1.1 mL fill) and 200 mg TG-2349 (50 mg/mL in PEG 400, 4.1 mL fill), are filled into 5-mL type 1 glass syringes. Required doses during clinical study are to be dispensed using the combination of the two dose units. The entire content of the syringe is to be taken by mouth.

Panel I (TG-2349); Panel II (TG-2349); Panel III (TG-2349); Panel IV (TG-2349); Panel IX (TG-2349); Panel V (TG-2349); Panel VI (TG-2349); Panel VII (TG-2349); Panel VIII (TG-2349); Panel X (TG-2349); Panel XI (TG-2349); Panel XII (TG-2349); Panel XIII (TG-2349); Panel XIV (TG-2349); Panel XV (TG-2349); Panel XVI (TG-2349)

placebo DRUG

Available in two different unit doses, 1.1 mL and 4.1 mL PEG 400 in 5-mL type 1 glass syringes. They are identical in appearance and similar in weight to TG-2349 oral liquid syringes.

Panel I (placebo); Panel II (placebo); Panel III (placebo); Panel IV (placebo); Panel IX (placebo); Panel V (placebo); Panel VI (placebo); Panel VII (placebo); Panel VIII (placebo); Panel X (placebo); Panel XI (placebo)

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• East Asian or Caucasian subjects, male or female, and 18 to 65 years of age inclusive
• Body mass index (BMI) in the range of 19.0 to 30.0 kg/m2 and body weight ≥ 50 kg inclusive
• In generally good physical and mental health status on the basis of a medical history review, medical evaluation including vital signs and physical examination, 12-lead ECG, and laboratory results at screening
• For females, one of the following criteria must be fulfilled:
• At least 1 year post menopausal, or
• Surgically sterile, or
• Willing to use a double barrier method \[intrauterine device (IUD) plus condom, spermicidal gel plus condom\] of contraception from screening until 30 days after the last dose of study drug
• Males must be willing to use a reliable form of contraception (use of a condom or a partner fulfilling the above criteria) from screening until 30 days after the last dose of study drug
• Willing to abstain from caffeine- or xanthine-containing beverages, including coffee and tea, alcohol, grapefruit juice, and Seville oranges during the stay-on-site period
• Willing and able to provide written informed consent

You may not qualify if:

• Positive serological test for IgM anti-HAV antibody, HBsAg or anti-HCV antibody at screening
• Positive ELISA test for HIV-1 or HIV-2 at screening
• Any abnormal laboratory values at screening: Hemoglobin (Hb) \<12.0g/dL for women and \<13.0g/dL for men, white blood cell count (WBC) \<3,000 cells/mm3, absolute neutrophil count \<1,500 cells/mm3, platelet count \<100,000 cells/mm3, serum creatinine ≥ 2 mg/dL, ALT or AST levels ≥ 2 xULN, total bilirubin
• ≥ 1.5 x ULN, INR (International Normalized Ratios for prothrombin time) ≥ 1.5 xULN
• Any abnormal laboratory values that are considered clinically significant by the Investigator at screening
• QTcF greater than 450 msec for females and 430 msec for males at screening
• History of renal, hepatic impairment, stomach or intestinal surgery or resection, malabsorption syndrome
• History of seizures, epilepsy, cardiovascular, diabetes or cancer (except basal cell carcinoma)
• History or family history of prolonged QT interval or family history of sudden cardiac death at a young age
• History of drug allergy or hypersensitivity, especially to sulfa drugs
• History or evidence of abuse of alcohol, barbiturate, amphetamine, recreational or narcotic drug use within 6 months prior to first dose of study drug administration
• Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of a psychiatric illness, or have any history of suicide attempt or depression
• Anemia or blood/plasma donation within 30 days prior to first dose of study drug administration
• Pregnant or breast-feeding
• Use of tobacco or nicotine-containing products within 30 days prior to first dose of study drug administration

Sponsors & Collaborators

• TaiGen Biotechnology Co., Ltd.: lead

Study Sites (1)

WCCT

Cypress, California, 90630, United States

Location

MeSH Terms

Conditions

Hepatitis C, Chronic

Condition Hierarchy (Ancestors)

Hepatitis C; Blood-Borne Infections; Communicable Diseases; Infections; Hepatitis, Viral, Human; Virus Diseases; Flaviviridae Infections; RNA Virus Infections; Hepatitis, Chronic; Hepatitis; Liver Diseases; Digestive System Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Nicole Sims, DO

  WCCT

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 13, 2011
• First Posted: February 1, 2012
• Study Start: October 1, 2011
• Primary Completion: April 1, 2012
• Study Completion: July 1, 2013
• Last Updated: December 19, 2014

Record last verified: 2014-12

Locations

US (1)